Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-04-30

Clinical Trial Update: A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase II trial evaluating ofatumumab in Waldenström macroglobulinemia; the study has completed and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Arzerra (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Waldenstrom Macroglobulinaemia | Phase 2 | Status: COMPLETED | Results posted: 2012-04-30